ANGLE PLC (LON:AGL)

ANGLE PLC (LON:AGL)


Share Price
60.00 p
Change
1.5 (2.56 %)
Market Cap
£86.09 m
Proactive Investors - Run By Investors For Investors

ANGLE PLC RNS Release

Notice of Results


RNS Number : 5452M
Angle PLC
09 January 2019
 
For Immediate Release
9 January 2019

 

 

ANGLE plc

("ANGLE" or "the Company")

 

Notification of Interim Results and Webcast

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, will be releasing its interim results for the six months ended 31 October 2018 on Thursday 31 January 2019. 

 

A meeting for analysts will be held at 12.30pm on 31 January 2019 at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London EC1A 4HD. 

 

A live webcast of the analyst meeting will also be available on ANGLE's Investor Centre page, http://www.angleplc.com/investor-information/investor-centre/. Please log on to the web address approximately 5 minutes before 12.30pm on the day of the results.

 

A recording of the webcast will also be made available on ANGLE's website, www.angleplc.com, following the results meeting.

 

 

For further information:

 

ANGLE plc

+44 (0) 1483 343434

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 


finnCap Ltd (NOMAD and Joint Broker)

Corporate Finance - Carl Holmes, Simon Hicks, Max Bullen-Smith

ECM - Alice Lane

 

+44 (0)20 7220 0500

WG Partners (Joint Broker)

Nigel Barnes, Nigel Birks, Andrew Craig, Chris Lee

 

+44 (0) 203 705 9330

 

 

FTI Consulting

Simon Conway, Stephanie Cuthbert, Ciara Martin

Matthew Ventimiglia (US) 

 

+44 (0) 203 727 1000

+1 212 850 5612

 

 

For Frequently Used Terms, please see the Company's website on http://www.angleplc.com/the-parsortix-system/glossary/

 

 

Notes for editors

 

About ANGLE plc     www.angleplc.com 

ANGLE is a world leading liquid biopsy company with sample to answer solutions. ANGLE's proven patent protected platforms include an epitope-independent circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.

 

ANGLE's cell separation technology is called the ParsortixTM system and it enables a liquid biopsy (simple blood test) to be used to provide the cells of interest. CTCs enable the complete picture of a cancer to be seen as they allow DNA, RNA and protein analysis and the live cells harvested can be cultured. Parsortix is the subject of 21 granted patents in Europe, the United States, Canada, India, China, Japan and Australia and three extensive families of patents are being progressed worldwide. The system is based on a microfluidic device that captures live cells based on a combination of their size and compressibility. The Parsortix system has a CE Mark in Europe for the indicated use and FDA clearance is in process for the United States with a 400 subject study in metastatic breast cancer. ANGLE is seeking to be the first ever FDA cleared CTC harvesting system and only the third ever FDA cleared liquid biopsy test. ANGLE has undertaken 400 subject clinical verification studies in an ovarian cancer pelvic mass triage test that achieved best in class accuracy (ROC-AUC) of 95.1% and is being optimised.

 

ANGLE's analysis technology for proteins and nucleic acids of all types is called the HyCEAD Ziplex® platform and is based on a patented flow through array technology.  It provides for low cost, highly multiplexed, rapid and sensitive capture of targets from a wide variety of sample types.  A proprietary chemistry approach allows for the capture and amplification of over 100 biomarkers simultaneously in a single reaction.  The HyCEAD Ziplex system is ideal for measuring gene expression and other markers directly from Parsortix harvests and was used in the ovarian cancer pelvic mass triage test to achieve the 95.1% accuracy.

 

ANGLE's proprietary technologies can be combined to provide automated, sample to answer results in both centralised laboratory and point-of-use cartridge formats. 

 

ANGLE has established formal collaborations with world-class cancer centres and major corporates such as QIAGEN, Abbott and Philips, and works closely with leading CTC translational research customers.  These Key Opinion Leaders (KOLs) are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies. The body of evidence as to the benefits of the Parsortix system is growing rapidly from our own clinical studies in metastatic breast cancer and ovarian cancer and also from KOLs with 13 peer-reviewed publications and 23 publicly available posters, available on our website.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NORBUGDBLUGBGCI

ANGLE PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use